Cerenome, Inc.
As of Oct 22, 2026, Cerenome is in Stage 4, the downtrend phase, now in week 17 (since Jun 29, 2026). It closed at $1.75, 90.3% below its 52-week high and below its 200-day average, which is falling.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CNSY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CNSY among Biotechnology497th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …497 | CNSY | Stage 4 · wk 17 | 8 | −10.3% |
Cerenome: quick answers
What stage is Cerenome in?
As of Oct 22, 2026, Cerenome (CNSY) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 29, 2026 and is in week 17. What the four stages mean
Is Cerenome in an uptrend?
No. Cerenome is in a Stage 4 downtrend. It trades 64.7% below its 200-day average, which is falling.
How far is Cerenome from its 52-week high?
Cerenome closed at $1.75 on Oct 22, 2026, 90.3% below its 52-week high of $18.00. Its 52-week low is $1.56.
How has Cerenome performed over the past year?
As of Oct 22, 2026, Cerenome is down 88.7% over the past year and down 87.5% so far in 2026.
Which sector and industry is Cerenome in?
Cerenome is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.